Pedro Cahn, M.D., Ph.D, is Professor of Infectious Diseases at the Buenos Aires University Medical School and Scientific Director of the Huesped Foundation. He earned his Doctor of Medicine degree from the University of Buenos Aires Medical School. Dr. Cahn has been working in infectious diseases for the last 45 years and involved in the HIV/AIDS arena since 1982. He founded the first infectious diseases unit within a public hospital in Argentina, the Infectious Diseases Division at the Juan A. Fernandez Hospital, where he has served as Division Chief and he is now Senior Consultant. He has been a member of the National AIDS Committee (Argentina) since 1988. He has been involved with international working groups and conferences on AIDS since 1989, including the 1st IAS Conference on HIV Pathogenesis and Treatment, and the XVII International AIDS Conference which he chaired. He is a Past-President of the International AIDS Society and an external advisor for UNAIDS, the World Health Organization (WHO), the Pan-American Health Organization, UNITAID, Doctors without Borders, as well as a member of the antiretroviral guidelines panel both for WHO and a former member of the guidelines panel of the International Antiviral Society-USA (IAS-USA). In 2014 Dr. Cahn received the distinction of Illustrious Citizen of the City of Buenos Aires and was awarded the Senator Domingo Faustino Sarmiento mention of Honor by the Honorable Argentine Senate. Dr. Cahn has published more than 190 peer-reviewed papers in international journals and has authored important book chapters.
Bonaventura Clotet, M.D., Ph.D, is Head of the Infectious Diseases Department of the Germans Trias i Pujol University Hospital, Director of the Retrovirology Laboratory IrsiCaixa Foundation, President of the Fight AIDS Foundation (Fundació Lluita contra la SIDA) and co-director of the HIVACAT program for the development of the AIDS vaccine in Catalonia, Spain. He received his MD and PhD at the Universitat Autònoma de Barcelona (UAB). At the academic level, he is associate professor of Medicine at the UAB and Chair of the Faculty of AIDS and related illnesses at the Central University of Catalonia. He is member of the steering committee of EuroSIDA (multicenter group for the study of AIDS in Europe) and he has been member of the Drug Resistance Mutations Group (IAS-USA) and of the Governing Council of the IAS. He also participates in the organizing committee and scientific committee of several international AIDS and Vaccine conferences. He is on the editorial board of AIDS Journal, HIV Medicine, Expert Review of Clinical Immunology, Future HIV Therapy and Journal of the International Association of Physicians in AIDS Care. He has received numerous awards among them the “Creu de Sant Jordi” one of the highest civil distinctions awarded the Generalitat of Catalonia and the award by the Catalan Institute of Health for his lifetime scientific career. In April 2013, he was named Doctor Honoris Causa by the University Carol Davila in Bucharest (Rumania). He has published more than 800 papers in international journals.
Dr Giovanni Guaraldi is a Assistant Professor of Infectious disease at University of Modena and Reggio Emilia (Italy). He is Modena university Rector Delegate for Cooperation and Development. Since the year 2000 he lead a liver and kidney transplant program for people with HIV infection at the m ultivisceral transplant centre at Policlinico of Modena. Since 2002 he runs a Metabolic Clinic for HIV infection. This tertiary level referral center offer a multidisciplinary team consultant service consisting of infectious disease physicians, nutritionists, personal trainers for physical activities, psychologists, cardiologist, nephrologists, endocrinologists and plastic surgeons for diagnosis and treatment of Non infectious Co-Morbidities. More than 4500 people are in charge of the Metabolic Clinic. He is a panel member of the European AIDS Clinical Society (EACS) guidelines on prevention and management of HIV associated co-morbidities . He has published widely on clinical aspects of HIV treatment and care.
Dr Mallon is Associate Dean for Research and Innovation within the School of Medicine, University College Dublin and an Infectious Diseases Specialist at the Mater Misericordiae University Hospital, Dublin. Dr Mallon heads the HIV Molecular Research Group, which focuses on translational research into toxicities of antiretroviral therapy, including cardiovascular disease, adipose tissue toxicity and bone disease. He sits on the European AIDS Clinical Society (EACS) Guidelines Panel and is widely published in the field of HIV/AIDS.
Dr. Eugènia Negredo completed the specialty of Internal Medicine at the Sant Pau Hospital, Barcelona, in 1998. She received her Ph.D. in Medicine from the Autonomous University of Barcelona, in 2002. Since 1999, Dr. Negredo works as a physician in the HIV Unit of Germans Trias i Pujol Hospital in Barcelona, and she leads the research group focused on the epidemiology, pathogenesis and treatment of different HIV- and antiretroviral-related complications. She is also Associate Professor of Universitat Autònoma de Barcelona and Universitat de Vic.
Cécile Tremblay is an infectious diseases/medical microbiologist specialist and the Université de Montréal/Pfizer Chair on Translational HIV Research. She is full professor in the Department of Microbiology, Immunology, and Infectious Diseases at University of Montreal and a researcher at Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CHUM). She obtained her M.D. at University of Montreal in 1992. She did her residency in medical microbiology and infectious diseases at University of Montreal and was certified by the Royal College of Physician of Canada in 1997. She then pursued a post-doctoral fellowship in HIV research at Massachusetts General Hospital, Harvard Medical School. She came back to Montreal in 2001, where she developed a research program focused on studying the virological determinants of HIV disease progression as well as molecular pathways involved in drug resistance. She is the founder and director of a pan-Canadian cohort of HIV-infected subjects with slow disease progression, which is a collaborative effort by Canadian researchers to better understand HIV immunopathology. She is also coordinating a research initiative on premature aging and cardiovascular disease in HIV in Canada. From 2012 to 2015, she served as Director of the Laboratoire de Santé Publique du Québec (Quebec Public Health Laboratory). During her mandate, she developed a research program on HIV epidemiology in Québec and was responsible for the coordination of the laboratory response to biological threats and emerging infectious diseases.
She has been involved in several initiative on HIV prevention both in West Africa as well as in Canada. She was the Canadian principal investigator for the Ipergay trial which demonstrated the efficacy of pre-exposure prophylaxis in a population of gay men. She has set up a prospective cohort of MSM to study the uptake of PrEP and its impact on HIV incidence. She is piloting several projects on HIV prevention in various key populations such as people from HIV endemic countries living in Quebec and vulnerable indigenous populations. She is the P.I. of an Ebola vaccine trial in HIV-infected individuals. She is now the Director of the Réseau SIDA-Maladies Infectieuses supported by the Fonds de Recherche du Québec en Santé.
Conflict of interest disclosures
Bonaventura Clotet has received research support grants, and fees as consultant and speaker from ViiV Healthcare and Merck Sharp & Dohme Corp.
Eugènia Negredo has received research support grants from Gilead, Merck Sharp & Dohme Corp., ViiV Healthcare and Janssen and honoraria or consultation fees from ViiV Healthcare and Merck Sharp & Dohme Corp.
Pedro Cahn has received research support grants from Abbie, Merck and ViiV Healthcare, received honoraria or consultation fees from ViiV Healthcare and Merck Sharp & Dohme Corp. and fees as a speaker from Abbvie and Merck.
Giovanni Guaraldi has received research support grants from ViiV Healthcare and Merck and received honoraria or consultation fees from ViiV Healthcare, Gilead, Merck and Jensen.
Cécile Tremblay has received research support grants, and honoraria or consultation fees from ViiV Healthcare and Merck Sharp & Dohme Corp and participated in a Merck Sharp & Dohme Corp sponsored speaker’s bureau
Patrick Mallon has received research support grants from GSK-ViiV Healthcare (Ireland), Gilead Sciences and Janssen Cilag, and received honoraria or consultation fees from Gilead Sciences, Bristol Myers Squibb, Janssen Cilag and MSD.